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Polycystic ovary syndrome (PCOS) is the most frequent cause of female infertility. The treatment of PCOS patients with insulin
sensitizers, such as metformin or thiazolidinediones, increases the ovulation rate and the number of successful pregnancies. The
positive action of the insulin-sensitizing treatments could be explained by a decrease in the peripheral insulin resistance but also
by a direct action at the ovarian level. We report in this review diﬀerent hypotheses of thiazolidinediones actions to improve PCOS
(steroid secretion by ovarian cells ; insulin sensitivity in muscle and adipocyte and fat redistribution).
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most frequent
cause of female infertility, aﬀecting about 5–10% of women
in age of procreation [1]. Diagnostic criteria to establish
PCOS are controversial [1, 2], involving two among the fol-
lowing three 2003 Rotterdam’s criteria: ﬁrst, clinical and/or
signs of hyperandrogenism, second a chronic absence of
ovulation and ﬁnally, third, the increase of ovarian volume
and/or the presence of at least 12 follicles in the 2- to 9-mm
range in each ovary, detected by ultrasonography [3]. More-
over,insulinresistanceisacommonmetabolicfeatureassoci-
ated withPCOS, up to 50–70% of patients in some series [4].
Yen et al described a vicious circle where several en-
docrineabnormalitiescouldmaintainthePCOSstatus[2,5].
Three entrance points are proposed as follows.
(1) Alteration of the hypothalamo-pituitary axis (∼ 50%
cases) [6] with high circulating LH levels that can lead
to excess androgens and contribute to the formation
of cystic follicles, as described in the mouse model [7].
However, the importance of this hypothesis as an en-
trance point is critical in the PCOS syndrome [8].
(2) Hyperandrogenismduetosteroidogenicdysregulation
in thecal cells. Mutations of Cyp11a1 or Cyp17 genes
are detected in some patients and could lead to an hy-
peractivity of the steroidogenesis [9, 10].
(3) As evidenced by Franks et al, hypersensitivity of ovar-
ian cells to both insulin and gonadotropin leads to an-
drogens hypersecretion [11].
The treatment of PCOS patients with insulin sensitizers
of various drug families, such as thiazolidinediones (TZDs),
metformin or D-chiro-inositol, increases the ovulation rate
and the number of successful pregnancies (cf [14–17]). The
positive action of these “insulin sensitizers” drugs could be
explained by various manners. We report in this review dif-
ferent hypothesis of TZDs actions to improve PCOS at each
level of the “Yen vicious circle” (Figure 1).
TZDs are synthetic ligands also known as glitazones (tro-
glitazone,rosiglitazoneorpioglitazone)[18],whichcanbind
and activate the nuclear receptor, peroxysome proliferator-
activated receptor gamma (PPARγ) (cf [19, 20]). PPARγ
could be considered as a fuel sensor linking the energy
metabolism and reproduction to inform cells on the en-
ergy status. Indeed, PPARγ can regulate the transcription
and/or activity of diﬀerent key regulators of energy home-
ostasis [19] such as glucose or lipid regulators (PPARγ
upregulated expression of glucose transporters, insulin re-
ceptor, insulin receptor substrate, fatty acid-binding pro-
tein, etc) (cf [21]). Activation of PPARγ by TZDs increases
insulin sensitivity mainly in adipocytes and muscle cells
[22], and also stimulates the diﬀerentiation of adipose cells
(cf [23, 24]).2 PPAR Research
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Figure1:PositiveactionsofTZDsinPCOSpatientsleadingtospontaneousovulation.Threeentrancepoints/majorendocrineabnormalities
(hyperandrogenia, insulin resistance, or LH hypersecretion) lead or maintain the ovulatory dysfunction of PCOS as represented in the inner
circle of the ﬁgure. For example, high LH concentrations or insulin increase androgen secretion by human thecal cells [12] and could
contribute to impair follicular development. In addition, elevated androgens could reduce hypothalamic sensitivity to negative steroids
feedback, because administration of ﬂutamide, an antiandrogen, can restore this sensitivity [13]. The positive actions of TZDs on PCOS
patients could be mainly at two levels as described in the outer part of the ﬁgure. (1) TZDs increase the insulin sensitivity and decrease the
insulin secretion. (2) TZDs reduce the androgen secretion and/or activity (in ovary and/or in adipose tissue). Finally, TZDs can modulate
secretion of several endocrine hormones (adiponectin, resistin, TNFα) which can reduce androgen production or improve gonadotropin
secretion. The boxes show results obtained in vivo in PCOS women (in bold) or in vitro in human cell culture (in italics).
In addition, the three PPAR isoforms (PPARα,P P A R β/δ,
PPARγ) are expressed along the gonadotrope axis (central
nervous system, pituitary gland and ovary) (cf [25, 26]). In
the ovaries, expression of PPARγ is restricted to follicles, pri-
marily to granulosa cells in developing follicles, slightly in
thecacellsandincorpusluteum(cf[25]).AftertheLHsurge,
the PPARγ expression decreases in follicle [27, 28]. In gen-
eral, it is considered that TZDs activate PPARγ, nevertheless
aPP ARγ-independentactionofTZDscannotbeexcluded,as
suggested by several recent studies [29, 30].
ASSESSMENT OF THE CLINICAL TRIALS OF
TZDS TREATMENTS
Pioglitazone and rosiglitazone are the unique TZDs which
could be used. Indeed, troglitazone was withdrawn from the
worldwide market in 2000 because of its hepatotoxicity. Pi-
oglitazoneandrosiglitazonepossessmainlythesameproper-
ties, except that pioglitazone may have a more positive eﬀect
on lipid proﬁle than rosiglitazone [31].
Administration of TZDs (troglitazone, rosiglitazone, pi-
oglitazone) is able to induce ovulation, to increase the ovu-
lation rate and pregnancy in PCOS (cf [32]). For example, a
large trial performed on 305 women has shown spontaneous
ovulation in over 50% of the time (600mg troglitazone) in
comparison with approximately 10% of placebo group [33].
Troglitazone [33–36], pioglitazone [37–40], and rosiglita-
zone [41–43], for at least 3 months of treatment, improved
insulin sensitivity, decreased the insulin concentration and
reduced the androgenic activity. In these studies, a decrease
in total and free circulating androgen concentrations asso-
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SHBG, levels was observed. Concentrations of progesterone
in serum are equivalent [35, 37], whereas those of estradiol
are equivalent or decreased [36] after TZDs treatment. The
body mass index is not signiﬁcantly changed with the three
TZDs [35–37, 39, 43, 44].
Furthermore, in PCOS patients with a “resistance” to
antiestrogens (such as clomiphene citrate), an association of
clomiphene citrate with TZDs (troglitazone, rosiglitazone)
can help to increase the ovulation rate [45, 46]. Thus, TZDs,
by an unknown mechanism (direct or indirect actions on
hypothalamo-pituitary axis in order to remove the negative
feedback of estradiol) could improve the clomiphene citrate
sensitivity in PCOS patients.
TZDs treatment improves the rate of spontaneous preg-
nancy in several trials (20–40% pregnancy success) [33, 41,
44, 45, 47]. We can note that pioglitazone and rosiglita-
zone are both classiﬁed by the FDA (food and drug ad-
ministration) as pregnancy category C and present poten-
tial teratogenic risks. PPARγ is important for embryonic de-
velopment [48] and TZDs can cause a decrease in the fe-
tal maturation [49]. Nevertheless, two reported cases of hu-
man exposure to rosiglitazone during pregnancy have shown
no malformation on babies [50, 51]. Despite this observa-
t i o n ,w o m e nt r e a t e dw i t hT Z D sw i l lb es t o p p e da ss o o na s
they will be pregnant. Similarly, preliminary studies have re-
vealed that metformin, an insulin sensitizer more studied
than TZDs, reduces also pregnancy losses, which are fre-
quently observed (30–50%) in PCOS women during the ﬁrst
trimester [52, 53]. No risk for the fetus or teratogenicity
was described after metformin administration (category B).
However, it appears premature to maintain currently such
treatments during pregnancy since there is no formal con-
sensus about such indication [54].
TZDS DID NOT SEEM TO AFFECT GONADOTROPIN
SECRETION
In most trials, after TZDs treatment (troglitazone, rosiglita-
zone or pioglitazone), basal gonadotropin levels or the lu-
teinizing hormone (LH)/follicle stimulating hormone (FSH)
ratio did not change with the therapy [33, 35, 37, 42, 43]. In
addition, recently, no alteration of the LH pulse frequency
and amplitude, as well as gonadotropin responses to GnRH,
was observed after pioglitazone treatment, either with or
without insulin infusion [55]. Nevertheless, in some trials,
a decrease in the plasma luteinizing hormone concentrations
was observed after troglitazone, rosiglitazone or pioglitazone
treatment [36, 38, 39, 44].
DIRECT ACTION OF TZDS ON OVARY
Several studies in ruminants have shown a direct eﬀect of
glucose or fatty acids on folliculogenesis. The ovulation rate
is increased without modiﬁcation of gonadotropin secretion
as observed in case of ﬂushing [56]. In this perspective, we
cannot reject the hypothesis for a direct action of TZDs on
ovary.
PPARγ didnotmodifyfolliculogenesisorovulation
rateinrodents
Activation of PPARγ by administration of 1mg of ciglita-
zone/day injected intraperitoneally during four weeks in rats
[57]didnotalterfolliculogenesisorthenumberofcorpuslu-
teum. In mice, deletion of PPARγ speciﬁcally in ovaries did
not change folliculogenesis or ovulation rate but decreased
the number of embryos implanted, probably due to a drop in
progesterone secretion by the corpus luteum [58]. Moreover,
in human, linkage studies have rejected a genetic association
between the PPARγ locus (3p25) and the birth of dizygotic
twin [59].
PPARγ modifysteroidssecretionbygranulosa
andthecalcells
In vitro, the steroids secretions (androgens, progesterone,
estradiol) are inhibited or stimulated (about 20%) by TZDs
according to species or the status of the cell diﬀerentiation
(follicular phase, before or after the preovulatory surge).
For example, TZDs stimulated progesterone secretion by a
mixture of granulosa, theca, and stroma human cells ob-
tained from premenopausal/perimenopausal patients at the
time of oophorectomy [60], and TZDs inhibited testosterone
secretion (
￿15% reduction, [60]), progesterone and estra-
diol by human granulosa cells (after hCG stimulation for in
vitro fertilization) or by luteal-granulosa cells obtained from
PCOS patients [61, 62]. Furthermore, TZDs inhibited in
vitro, LH/insulin-stimulated androgens secretion by porcine
thecal cells [63].
Inanycase,theinhibitingeﬀectofTZDs,inhumanovar-
iancells,ismoreduetoareductionintheactivityofsteroido-
genic enzymes 3-beta-hydroxysteroid-dehydrogenase (3β-
HSD) and aromatase, rather than an activation of PPARγ on
the promoters of the genes encoding these enzymes [61, 64].
Improved insulin sensitivity in ovary induced by TZDs
could also favor the restoration of steroidogenesis to a nor-
mal status. Indeed, the responsiveness to FSH in human
granulosa cells obtained in PCOS patients was enhanced by
insulin after improvement of the insulin sensitivity induced
by the pioglitazone treatment [65]. In addition, in prelimi-
naryresults,pioglitazoneandrosiglitazoneincreasedbytwo-
tothree-foldthelevelofinsulinreceptorandinsulinreceptor
substrate-1 in human ovarian cells [66].
IMPROVEMENT OF THE METABOLIC STATUS BY TZDS
INCREASES FERTILITY IN PCOS PATIENTS
Thus, TZDs can act on the ovary in order to regulate ster-
oidogenesisbyadirectactiononthecaandgranulosacellsvia
PPARγ. Nevertheless, the actions of TZDs on steroidogene-
sis are not drastic and are varied in function by the status of
the celldiﬀerentiation (and species). It will be more probable
that a general improvement (redistribution of the fat tissue,
increased in insulin sensitivity and inhibition of hepatic glu-
coneogenesis) stimulates ovulation through multiple ovary-
independantmechanisms.Theobservationsdescribedbelow4 PPAR Research
areinfavourforthisindirectactionofTZDsinthetreatment
of PCOS.
TZDsincreaseinsulinsensitivity
TZDs reduce insulin resistance by improving sensitivity to
insulin, mainly in adipose tissue and muscle of PCOS pa-
tients [22, 67]. TZDs could stimulate glucose transporter ex-
pression and other proteins in the insulin pathway (cf [21]).
Moreover, a decrease in the insulin resistance by TZDs could
be explained by a redistribution of the triglycerides circu-
lating or content in liver and skeletal muscle into the adi-
pose tissue. These modiﬁcations are associated with a de-
crease in plasma free fatty acid and triglyceride concentra-
tions [22, 68]. Free fatty acid and/or triglyceride concentra-
tions are high in PCOS patients [69] and decrease after TZDs
treatment (cf [70]).
With this improvement of the general status, spontane-
nous ovulation could be favored. For example, only a weight
reduction by diet and exercise improved insulin sensitivity
and led to restoration of normal cycles. A 10–15% weight re-
duction couldreduce hyperandrogenism and restored ovula-
tion in more than 75% of PCOS obese patients [71, 72].
TZDscoulddecreaseandrogensynthesisby
afattissueredistribution
TZDs can decrease the high free androgen activity by two
mechanisms: an increase in SHBG levels in serum, leading
to a decrease in free circulating androgen levels [39], an adi-
pose tissue redistribution. In contrast to metformin, a long-
term TZDs treatment increases the body fat mass due to an
increase in the subcutaneous adipose tissue [73]a n dad e -
crease in the amount of visceral abdominal adipose tissue
associated with a decrease in free fatty acid [74]. The vis-
ceral fat mass has been associated with high serum androgen
concentrations and was closely related to insulin resistance
in women with PCOS [75, 76]. Thus, the reduction in the
amount of profound visceral abdominal adipose tissue could
contribute to explain the decrease in the testosterone and
estradiol production, and consequently the improvement of
the gonadotrophins pulsatility.
TZDscouldrestoreadipokinessecretionimplied
inreproduction
Not only adipose tissue is involved for an energy storage,
but also adipocytes secrete also hormones (TNFα, leptin,
adiponectin, resistin, etc) which help to maintain homeosta-
sis. These hormones are also implied directly in the reg-
ulation of the fertility at each level of the hypothalamo-
pituitary-gonads axis (cf [77]). Moreover, the increased mass
oftheadiposetissueinPCOSpatientsaltersthehormonalse-
cretion (higher circulating levels of TNFα, resistin and lower
levels of adiponectin [78, 79]). However, TZDs-induced re-
turn to a “normal metabolic state” may lead to a normal
hormonal secretion by adipocytes. TZDs via PPARγ stim-
ulate adipocyte diﬀerentiation and increase the number of
smaller adipocytes that are highly insulin sensitive [80–82].
These small adipocytes produce fewer free fatty acids, TNFα
and leptin [81]. In addition, TZDs stimulate adiponectin
secretion by adipocytes in vitro [83], and adiponectin lev-
els were increased in PCOS women treated by rosiglitazone
[84]. Adiponectin sensitizes cells to insulin and inhibits re-
sistin secretion by adipocytes, which antagonizes the in-
s u l i na c t i o n[ 73, 85]. Furthermore, in vitro, human thecal
cells stimulated previously by insulin or forskolin, and then
treated with resistin, have shown an increased activity of the
p450c17 enzyme, leading to a stimulation of the androgens
secretion [86].
COMPARISON BETWEEN METFORMIN AND TZDS
MetforminseemstoimprovefertilityofPCOSpatientsandis
commonly used as an adjuvant to general lifestyle improve-
ments [87, 88]. Metformin acts by a decrease of peripheral
insulin resistance but new results suggest that metformin can
regulate directly folliculogenesis at the ovarian level. In vitro
in rat hepatocytes or in vivo in the human skeletal muscle,
metformin activates AMP-activated protein kinase (AMPK),
a regulator of energy balance [89]. In rat granulosa cells,
activation of AMPK-induced by metformin decreases pro-
gesterone secretion, and the levels of proteins implied in
steroidogenesis (3β-HSD, CYP11a1, STAR, and CYP19A1)
[90]. Moreover, in human granulosa cells, metformin de-
creases progesterone secretion [91] and androgens synthe-
sis through a direct inhibition of the Cyp17 activity [92].
Recently, AMPK was described to be activated indirectly by
TZDs and independently of PPARγ [30]. These two insulin-
sensitizing agents (metformin and TZDs) cause a rapid in-
creaseinthecellularADP:ATPratio,probablyduebythein-
hibition of the respiratory chain, which can lead to the phos-
phorylation of AMPK [93].
Interestingly, PCOS women treated with metformin
present lower follicular ﬂuid concentrations of testosterone
and insulin and after gonadotropin-stimulation for in vitro
fertilization, the number of mature oocytes retrieved and
oocytes fertilized was increased in comparison with con-
trols [94].
Comparative studies [47, 95–97] performed between the
two treatments (metformin and TZDs) have shown similar
[47, 96]o rb e t t e rp e r f o r m a n c e[ 96, 97] for TZDs to im-
prove regular menstrual cyclicity (87.8% with rosiglitazone
versus 79.3% with metformin, [96]), the ovulation rate and
the pregnancy rate in PCOS patients.
The diﬀerent mechanism used by metformin and by
TZDs to improve fertiliy induces new possibility in the treat-
ment of PCOS. For example, one clinical trial has tested
co-administration of pioglitazone and metformin to PCOS
womennonoptimallyresponsivetometformin.Thepercent-
age of menses increased two-fold after co-administration in
comparison, with only metformin-treated women [98].
CONCLUSION
Overall, insulin-sensitizing treatments for PCOS patients,
such as metformin or TZDs, lead to a strong improvementP. Froment and P. Touraine 5
of the fertility. These treatments have several sites of action
(steroid secretion by ovarian cells; insulin sensitivity in mus-
cle and adipocyte and fat redistribution). More and more
clinical data are now available and encourage us to redeﬁne
our approach of insulin resistance, and the treatment of in-
fertility in patients with PCOS.
Creation ofpromising ligand, forexample a dualPPARα/
PPARγ agonist (glitazar class) [99, 100], could be useful to
treat insulin sensitivity, atherosclerotic vascular, and fertil-
ity in PCOS women. Nevertheless, before using it in rou-
tine clinical practice, several extended safety tests should be
necessary to estimate the potential risk of these synthetic
ligands.
ItisalsonecessarytokeepinmindthatTZDscanpresent
a risk to the fetus during pregnancy and therefore their use
should be carefully monitored, especially during the ﬁrst
weeks of pregnancy. Finally the development of animal mod-
els, mimicking PCOS is probably mandatory in next few
years to increase our knowledge on this syndrome and to
better understand the molecular actions of metformin and
TZDs in target organs.
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